GRENOBLE, France--(BUSINESS WIRE)--
CEA-Leti and Capsum today announced that the successful transfer of Letis patented Lipidots nanovector technology to Capsum for cosmetic applications has produced the first commercial use of the new technology.
Lipidots is a versatile nano-delivery platform based on tiny droplets of oil for encapsulating and carrying drugs or fluorescent imaging agents to targeted cells in the body for treatment or diagnosis. Letis partnership with Capsum shows that the technology is easily adapted for applications in the cosmetics industry.
Capsum adapted the Lipidots technology for its NeoGoutttesTM, nano-emulsions that are used as a component in finished products and that provide a very efficient way of vectorizing lipophilic or hydrophilic concentrates of active ingredients. The nanovector encapsulation protects active ingredients, so they are conveyed through the skin for optimal effect.
Technology transfer to our partners for commercialization of our research results is a critical part of Letis mission, said Patrick Boisseau, head of Letis nanomedicine program. The success of our project with Capsum demonstrates that the Lipidots nanovector technology can be scaled up from laboratory to industrial production easily and efficiently, and that it is well suited for a non-medical application like cosmetics.
Capsum is focused on providing innovative ways to design and develop cosmetics by incorporating the best science within creative product design, said Sbastien Bardon, Capsum CEO. Letis Lipidots technology is a breakthrough that strongly enhances our encapsulation systems, and offers more ways for our customers to bring their products to market.
The successful technology transfer follows more than seven years of collaboration between Leti and Capsum that included development work on Lipidots.
This successful technology transfer is the second recent announcement about Lipidots. In July, Leti announced 1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815. LipImage 815 is a fluorescent imaging agent based on Lipidots that carries a fluorescent substance to targeted cells. It will be used to test for early stages of liver cancer
About CEA-Leti
By creating innovation and transferring it to industry, Leti is the bridge between basic research and production of micro- and nanotechnologies that improve the lives of people around the world. Backed by its portfolio of 2,200 patents, Leti partners with large industrials, SMEs and startups to tailor advanced solutions that strengthen their competitive positions. It has launched more than 50 startups. Its 8,000m of new-generation cleanroom space feature 200mm and 300mm wafer processing of micro and nano solutions for applications ranging from space to smart devices. Letis staff of more than 1,700 includes 200 assignees from partner companies. Leti is based in Grenoble, France, and has offices in Silicon Valley, Calif., and Tokyo.
Go here to read the rest:
Leti Transfer of Lipidots (R) Technology to Cosmetics Maker Capsum Produces First Commercial Use of Nanovector ...